SLXN

Silexion Therapeutics Corp

Add to Watchlist

Advanced Chart

7.180

+0.38(5.588%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.225

Open

6.800

VWAP

6.84

Vol

26.38K

Mkt Cap

5.25M

Low

6.660

Amount

180.37K

EV/EBITDA(TTM)

Total Shares

731.64K

4.70M

EV/OCF(TTM)

P/S(TTM)

Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

1 Analyst Rating

Wall Street analysts forecast SLXN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLXN is 75.00 USD with a low forecast of 75.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 7.180

Low

75.00

Averages

75.00

High

75.00

Current: 7.180

Low

75.00

Averages

75.00

High

75.00

Maxim Group

Naz Rahman

Strong Buy

Maintains

$9 → $5

2025-03-20

Reason

Maxim Group

Naz Rahman

Price Target

$9 → $5

2025-03-20

Maintains

Strong Buy

Reason

Maxim lowered the firm's price target on Silexion Therapeutics to $5 from $9 and keeps a Buy rating on the shares after its Q4 results. The company is progressing with its SIL-204, an updated formulation of its prior LODER therapy, a KRAS targeting siRNA therapy for treating non-resectable, locally advanced pancreatic cancer, though the firm is reducing its price target due to the additional dilution from the recent capital raise and warrant exercises, the analyst tells investors in a research note.

Maxim Group

Naz Rahman

Strong Buy

Initiates

2024-11-01

Reason

Maxim Group

Naz Rahman

Price Target

2024-11-01

Initiates

Strong Buy

Reason

Maxim initiated coverage of Silexion Therapeutics with a Buy rating and $1 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Silexion Therapeutics Corp (SLXN.O) is -0.56, compared to its 5-year average forward P/E of -0.11. For a more detailed relative valuation and DCF analysis to assess Silexion Therapeutics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.11

Current PE

-0.56

Overvalued PE

0.19

Undervalued PE

-0.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00